Interview with the Director of MitoAction.org; Cristy Balcells.
Organizations share what they have planned for the next 12 months. The annual town meeting is our way of kicking off the new year...
Join us for an informative webinar exploring KYGEVVI™ (doxecitine and doxribtimine), the first FDA-approved treatment for thymidine kinase 2 deficiency (TK2d) in adults and...
uy Miller, BioElectron’s CEO, and Matthew Klein, its Chief Medical Officer, will discuss the following: Challenges in the development of drugs for mitochondrial disease...